19.06.2013 - The University of Southern Denmark will host a new centre dedicated to genomics, proteomics and lipidomics analysis and biological network analysis.
The research infrastructure, which gained an €8m funding form the Villum Foundation, will be located at the Center for Bioanalytical Sciences of the university. "The grant is a huge boost to our interdisciplinary research programs in the biological sciences, " said Ole Jensen, who will head the new centre. "It provides us with new equipment to investigate complex biological systems, from individual biomolecules all the way to genomes, proteomes and metabolomes and systems-wide studies."
The centre will incorporate instrumentation for genomics, proteomics and lipidomics studies, and equipment and computers for detailed analysis of biomolecular structures, interactions and networks. "Integration of experimental and computational approaches is essential in modern biological research and this infrastructure grant provides us with a very strong platform for data storage, data integration and computational modelling of biomolecules and cellular networks, to the benefit of SDU researchers and their collaborators", said Jensen.
The University of Southern Denmark is already an established excellence centre for expression proteomics, pushed by funding of Denmark's government in the past.
19.11.2014 It’s not every day that a company is pushed into the top ten of its sector, but that day has come for Actavis. Christmas came early for the new pharma giant after completing a US$66bn (€53bn) takeover battle for the Botox manufacturer Allergan.
18.11.2014 Merck KGaA and US rival Pfizer have signed a immuno-oncology alliance worth billions: Merck will share the development and commercialisation of its cancer antibody with its US partner – for €2.3bn.
14.11.2014 Cosily coinciding with World Diabetes Day on 14th November, French biopharma Les Laboratories Servier has struck a US$1bn deal with US pharma Intarcia Therapeutics for the exclusive rights to Intarcia’s unprecedented therapy for type 2 diabetes.
12.11.2014 Glitz and glamour are not words often used to describe science and mathematics. But once a year, celebrities from the science and showbiz world come together at the Breakthough Prizes, a glitzy television bash that honours scientists for their achievements. French life scientist Emmanuelle Charpentier was among this year’s winners.
04.11.2014 Galecto Biotech has entered an agreement with Bristol-Myers Squibb for the acquisition of the company and its lead drug, providing the Swedish company with the potential of reaching over US$400m.